Pretreatment hyperuricemia and hypoalbuminemia as predictors for one-year mortality in diffuse large B-cell lymphoma beyond the international prognostic index

Thanawat Rattanathammethee

doi:10.69898/jhtm.36.2026.291863

Authors

Thanawat Rattanathammethee Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University

DOI:

https://doi.org/10.69898/jhtm.36.2026.291863

Keywords:

-

Downloads

Download data is not yet available.

References

International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329:987-94.

Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857-61.

Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123:837-42.

Annemans, L., Moeremans, K., Lamotte, M., Garcia Conde, J., van den Berg, H., Myint, H, et al. Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin's lymphoma in four European countries. Leuk Lymphoma. 2003;44:77-83.

Prochazka KT, Melchardt T, Posch F, Schlick K, Deutsch A, Beham-Schmid C, et al. NCCN-IPI score independent prognostic of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients. Br J Cancer. 2016;115:1264-72.

Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med. 2017;15:123.

Huang T, An Z, Huang Z, Gao W, Hao B, Xu J. Serum albumin and cardiovascular disease: a Mendelian randomization study. BMC Cardiovasc Disord. 2024;24:196.

Don BR, Kaysen G. Serum albumin: relationship to inflammation and nutrition. Semin Dial. 2004;17:432-437.

Wei X, Zheng J, Zhang Z, Liu Q, Zhan M, Huang W, et al. Consecutive Hypoalbuminemia Predicts Inferior Outcome in Patients With Diffuse Large B-Cell Lymphoma. Front Oncol. 2021;10:610681.

Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33:550-8.

Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trneny M, Sharman JP , et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386:351-63.

Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333:1540-5.